| Literature DB >> 27453044 |
Alexis Guernet1, Sathish Kumar Mungamuri2, Dorthe Cartier1, Ravi Sachidanandam2, Anitha Jayaprakash2, Sahil Adriouch3, Myriam Vezain4, Françoise Charbonnier4, Guy Rohkin2, Sophie Coutant4, Shen Yao2, Hassan Ainani1, David Alexandre1, Isabelle Tournier4, Olivier Boyer5, Stuart A Aaronson2, Youssef Anouar1, Luca Grumolato6.
Abstract
Intratumor genetic heterogeneity underlies the ability of tumors to evolve and adapt to different environmental conditions. Using CRISPR/Cas9 technology and specific DNA barcodes, we devised a strategy to recapitulate and trace the emergence of subpopulations of cancer cells containing a mutation of interest. We used this approach to model different mechanisms of lung cancer cell resistance to EGFR inhibitors and to assess effects of combined drug therapies. By overcoming intrinsic limitations of current approaches, CRISPR-barcoding also enables investigation of most types of genetic modifications, including repair of oncogenic driver mutations. Finally, we used highly complex barcodes inserted at a specific genome location as a means of simultaneously tracing the fates of many thousands of genetically labeled cancer cells. CRISPR-barcoding is a straightforward and highly flexible method that should greatly facilitate the functional investigation of specific mutations, in a context that closely mimics the complexity of cancer.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27453044 PMCID: PMC5537739 DOI: 10.1016/j.molcel.2016.06.017
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970